| NCT Number | NCT06563414 |
| Lead Sponsor | Krystal Biotech, Inc. |
| Conditions | Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans |
| Enrollment | 40 participants |
| Start Date | 2024-08-02 |
| Primary Completion | 2025-12 (estimated) |
| Study Completion | 2025-12 (estimated) |
| Updated on ClinicalTrials.gov | 2025-07-02 |